

FARMAKOTERAPIE BEHAVIORÁLNÍCH PROJEVŮ U FRONTOTEMPORÁLNÍ DEMENCE

**Wittebrood C et al. Farmakoterapie behaviorálních projevů
u frontotemporální demence: Konsensus odborníků z
Evropské referenční sítě pro vzácná neurologická onemocnění
(ERN-RND). Eur J Neurol. 2024 Dec;31(12):e16446. doi:
10.1111/ene.16446.**

EUROPEAN REFERENCE NETWORKS
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

Share. Care. Cure.



Odmítnutí odpovědnosti:

"Podpora Evropské komise pro vydání této publikace nepředstavuje schválení jejího obsahu, který odráží pouze názory autorů, a Komise nenese odpovědnost za jakékoli použití informací v ní obsažených."

Další informace o Evropské unii jsou k dispozici na internetu (<http://europa.eu>).

Lucemburk: Úřad pro publikace Evropské unie, 2019

© Evropská unie, 2019

Reprodukce je povolena pod podmínkou uvedení zdroje.

ÚVOD DO EVROPSKÉ REFERENČNÍ SÍTĚ PRO VZÁCNÁ NEUROLOGICKÁ ONEMOCNĚNÍ (ERN-RND)

ERN-RND je evropská referenční síť zřízená a schválená Evropskou unií. ERN-RND je zdravotnická infrastruktura, která se zaměřuje na vzácná neurologická onemocnění (RND). Třemi hlavními pilíři ERN-RND jsou (i) síť odborníků a odborných center, (ii) vytváření, sdružování a šíření znalostí o RND a (iii) zavádění elektronického zdravotnictví, které umožní, aby odborné znalosti cestovaly místo pacientů a rodin.

ERN-RND sdružuje 64 předních evropských odborných center a 4 přidružené partnery ve 24 členských státech a zahrnuje vysoce aktivní patientské organizace. Centra se nacházejí v Rakousku, Belgii, Bulharsku, Chorvatsku, Kypru, České republice, Dánsku, Estonsku, Finsku, Francii, Německu, Řecku, Maďarsku, Irsko, Itálii, Lotyšsku, Litvě, Lucembursku, Maltě, Nizozemsku, Polsku, Slovinsku, Španělsku a Švédsku.

ERN-RND pokrývá následující skupiny onemocnění:

- Ataxie a dědičné spastické paraplegie
- Atypický parkinsonismus a genetická Parkinsonova choroba
- Dystonie, paroxysmální porucha a neurodegenerace s akumulací železa v mozku
- Frontotemporální demence
- Huntingtonova choroba a jiné chorey
- Leukoencefalopatie

Konkrétní informace o síti, odborných centrech a zahrnutých onemocněních najdete na internetových stránkách sítě www.ern-rnd.eu.

Doporučení pro klinické použití:

Tento dokument uvádí nejdoporučovanější aplikované léčebné postupy pro různé poruchy chování spojené s frontotemporální demencí (FTD) na základě konsenzu 21 evropských odborníků. Tento konsenzus je podrobně popsán v publikaci Wittebrood C et al. s názvem "Pharmacotherapy for Behavioral Manifestations in Frontotemporal Dementia: European Journal of Neurology (2024 Dec; 31(12): e16446. doi: 10.1111/ene.16446).

Vzhledem k omezeným důkazům založeným na studiích týkajících se farmakologické léčby poruch chování u FTD má tento dokument sloužit jako praktický průvodce pro neurology a další odborníky při výběru vhodných možností léčby. Je důležité si uvědomit, že postupy zde popsané vycházejí z reálných zkušeností a nemusí nutně dokazovat účinnost.

VYLOUČENÍ ODPOVĚDNOSTI

U klinických pokynů, doporučených postupů, systematických souhrnných prací a další metodiky, které ERN-RND zveřejňuje, schvaluje či považuje za přínosné, se jedná o hodnocení současných vědeckých a klinických poznatků, které jsou k dispozici jako studijní materiály.

Je možné, že tyto informační materiály (1) nezmiňují veškeré možné způsoby léčby a péče o pacienta, a nelze je tudíž považovat za pečovatelské standardy; (2) nejsou průběžně aktualizovány, a možná tedy nereflektují nejnovější poznatky (v době mezi zpracováním a publikací resp. četbou či studiem informačního materiálu se vývoj může posunout opět o něco dále); (3) jsou zaměřeny jen na explicitně uvedenou tematiku; (4) nepředepisují konkrétní lékařskou péči; (5) nenahrazují nezávislý, profesionální názor ošetřujícího lékaře, jelikož nezohledňují individuální rozdíly mezi pacienty. Ošetřující lékař by měl v každém případě volit léčebný postup individuálně podle konkrétního pacienta. Využití těchto informací je dobrovolné. Informace

poskytované ERN-RND odrážejí současný stav poznatků a ERN-RND za ně neručí ani explicitně, ani implicitně. ERN-RND výslovně odmítá jakoukoliv záruku za praktickou použitelnost a vhodnost s ohledem na konkrétní způsob použití nebo konkrétní účel. ERN-RND nepřijímá žádnou odpovědnost za případnou újmu na zdraví nebo věcnou škodu, která vznikla na základě nebo v souvislosti s využíváním těchto informací, ani za případné omyly a opomenutí.

METODIKA

Schválení doporučení provedla skupina pro frontotemporální demenci ERN-RND. Schválení bylo dokončeno většinovým hlasováním.

Skupina onemocnění frontotemporální demenci:

Koordinátoři skupin nemocí:

Ana Sofia da Costa²⁹; Harro Seelaar¹⁵; Rik Vandenberghe³⁸; Robert Rusina³⁷

Členové skupiny nemocí:

Zdravotničtí pracovníci:

Albert Acewicz¹⁷; Alberto Albanese¹⁹; Andrea Mignarri⁶; Andreas Hermann⁴¹; Andreas Kouparis¹²; Ángel Martín²²; Annachiara Cagnin⁴; Anne Remes¹⁶; Archontia Adamou¹²; Atbin Djamshidian²⁵; Barbara Garavaglia¹⁸; Bernhard Landwehrmeier⁴⁰; Christos Koros¹³; Daisy Rinaldi⁷; Daniel Boesch²⁵; Dario Saracino⁷; David Crosiers²; David Mengel³⁹; Denes Zadori³²; Domenico Plantone⁶; Dominika Narowska¹⁷; Elena Salvatore³; Elisabeth Kapaki¹³; Eloy Rodríguez-Rodríguez²⁴; Fran Borovecki³⁵; Giuseppe Di Fede¹⁸; Hanne Gottrup¹; Heike Stockner²⁵; Henriette Klitt¹; Ivana Mokrišová²⁶; Jakub Hort²⁶; Joergen Nielsen²⁸; Johanna Krüger¹⁶; Johannes Levin²³; Jon Infante²⁴; Julie Martinková²⁶; Karolina Ziora-Jakutowicz¹⁷; Kathrin Reetz²⁹; Kevin Peikert⁴¹; Kirsten Klijnsma¹⁵; Laurine Virchien¹¹; Lena Hjerminde²⁸; Lenka Krajčovičová³¹; Manuel Menendez⁸; Marc Teichmann⁷; Margarete Delazer²⁵; Marina Boban³⁵; Marta Fernández-Matarrubia²⁴; Martin Vyhnálek²⁶; Menelaos Pipis¹²; Milica Kramberger⁴²; Nataša Peskar⁴²; Norbert Kovacs⁴³; Pierre Kolber⁹; Pietro Tiraboschi¹⁸; Pilar Delgado⁴⁴; Roberto Ceravolo⁵; Rose Bruffaerts²; Sabina Capellari²⁰; Sara van Mossevelde²; Sean O'Dowd²¹; Sokratis Papageorgiou¹³; Sylvia Boesch²⁵; Sylvia Boesch²⁵; Tatjana Muravska²⁷; Thibaud Lebouvier¹⁰; Tim Van Langenhove³⁶; Ülle Krikmann³³; Valentina Nicoletti⁵; Zeljko Uzelac⁴⁰; Zoltan Grosz³⁰; Zsolt Cséfalvay³⁴

Zástupce pacientů:

Lara Bruschinski¹⁴; Mary Kearney¹⁴

¹Univerzitní nemocnice Aarhus, Dánsko; ²Univerzitní nemocnice Antverpy, Edegem, Belgie; ³AOU - Univerzitní nemocnice Federico II, Neapol, Itálie; ⁴AOU - Univerzitní nemocnice Padova, Itálie; ⁵AOU - Univerzitní nemocnice Pisa, Itálie; ⁶AOU - Univerzitní nemocnice Siena, Itálie; ⁷APHP - Referenční centrum pro vzácné demence, nemocnice Pitié-Salpêtrière, Paříž, Francie; ⁸Asturias Central University Hospital, Oviedo, Španělsko; ⁹CHL - Luxembourg Hospital Center, Lucembursko; ¹⁰CHU de Lille, Francie; ¹¹CHU de Toulouse, Francie; ¹²Cyprus Institute of Neurology and Genetics, Egkomi, Kypr; ¹³Eginitio Hospital, National and Kapodistrian University of Athens, Řecko; ¹⁴ePAG; ¹⁵Erasmus University Medical Center Rotterdam, Nizozemsko; ¹⁶Finland Consortium; ¹⁷Institut psychiatrie a neurologie, Varšava, Polsko; ¹⁸IRCCS - Nadace neurologického institutu Carlo Besta, Milán, Itálie; ¹⁹IRCCS - Klinický institut Humanitas v Rozzanu, Milán, Itálie; ²⁰IRCCS - Neurologický

institut v Boloni, Itálie; ⁽²¹⁾Irské konsorcium: ²²Univerzitní nemocnice La Paz, Madrid, Španělsko; ²³Univerzitní nemocnice Ludwiga Maximiliana, Mnichov, Německo; ²⁴Univerzitní nemocnice Marques de Valdecilla, Santander, Španělsko; ²⁵Lékařská univerzita Innsbruck, Rakousko; ²⁶Fakultní nemocnice Motol, Praha, Česká republika; ²⁷Pauls Stradins Clinical University Hospital, Riga, Lotyšsko; ²⁸Rigshospitalet University Hospital Copenhagen, Dánsko; ²⁹RWTH - University Hospital Aachen, Německo; ³⁰Semmelweis University, Budapešť, Maďarsko; ⁽³¹⁾ St. Anne's University Hospital Brno, Česká republika; ³²Szent-Györgyi Albert Medical Center, Szeged, Maďarsko; ³³Tartu University Hospital, Estonsko; ³⁴Fakultní Thomayerova nemocnice, Praha, Česká republika; ³⁵University Hospital Center Zagreb, Chorvatsko; ³⁶University Hospital Ghent, Belgie; ³⁷University Hospital Hradec Králové, Česká republika; ³⁸Univerzitní nemocnice Leuven, Belgie; ³⁹Univerzitní nemocnice Tübingen, Německo; ⁴⁰Univerzitní nemocnice Ulm, Německo; ⁴¹Univerzitní lékařské centrum Rostock, Německo; ⁴²Univerzitní lékařské centrum Lublaň, Slovinsko; ⁴³Univerzita Pécs, Maďarsko; ⁽⁴⁴⁾Univerzitní nemocnice Vall d'Hebron, Barcelona, Španělsko.

Proces schvalování:

- Souhlas se schválením dokumentu celou skupinou nemocných - 10. března 2025

DOPORUČENÉ POSTUPY LÉČBY PORUCH BOBRA U FTD

Uvádíme zde nejčastěji doporučované léčebné postupy pro ty čtyři projevy chování, u nichž bylo dosaženo konsenzu (alespoň 2/3 odborníků zvolily alespoň jeden shodný léčebný postup). Pořadí představuje klesající počet hlasů odborníků pro příslušný lék:

Fyzická agrese

1. Quetiapin
2. Risperidon
3. Olanzapin
4. Trazodon
5. (Es)Citalopram

Verbální agrese

1. Quetiapin
2. Risperidon
3. (Es)Citalopram
4. Trazodon
5. Olanzapin

Obsedantní bludy.

1. Quetiapin
2. (Es)Citalopram
3. Risperidon
4. Setralin
5. Trazodon

Impulzivita

1. (Es)Citalopram
2. Trazodon
3. Quetiapin
4. Setralin
5. Risperidon

PŘÍLOHA: PŮVODNÍ PUBLIKACE (OD NÁSLEDUJÍCÍ STRANY)

ORIGINAL ARTICLE

Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND)

Casper Wittebrood¹  | Marina Boban^{2,3} | Annchiara Cagnin⁴  | Sabina Capellari^{5,6}  | François-Laurent De Winter¹ | Atbin Djamshidian⁷ | Manuel Menéndez González^{8,9,10} | Lena E. Hjermind¹¹ | Lenka Krajcovicova¹² | Johanna Krüger^{13,14,15} | Johannes Levin^{16,17,18} | Kathrin Reetz¹⁹  | Eloy Rodriguez Rodriguez^{20,21,22} | Jonathan Rohrer²³ | Tim Van Langenhove²⁴ | Carola Reinhard²⁵ | Holm Graessner^{26,27} | Robert Rusina²⁸ | Dario Saracino^{29,30} | Marion Houot^{31,32,33} | Harro Seelar³⁴ | Rik Vandenberghe¹

Correspondence

Casper Wittebrood, Department of Neurology, University Hospital Leuven, Leuven, Belgium.
Email: casper.wittebrood@uzleuven.be, casperwittebrood@msn.com

Abstract

Background and Purpose: Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on non-pharmacological and pharmacological approaches. Unfortunately, trial-based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers.

Method: The study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN-RND).

Results: The study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self-injury and self-harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.

For affiliations refer to page 9.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Conclusions: The survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.

KEYWORDS

drug therapy, expert testimony, frontotemporal dementia, neurobehavioural manifestations, neurodegenerative diseases

INTRODUCTION

Frontotemporal dementia (FTD) encompasses a spectrum of clinical syndromes characterized by frontal and temporal atrophy, manifesting as behavioural, personality and language changes. Frontotemporal lobar degeneration pertains to the underlying neurodegenerative pathological changes in FTD syndromes. Although there are a number of ongoing trials [1], at present there are neither proven nor US Food and Drug Administration or European Medicines Agency approved disease-modifying treatments for FTD. Therefore, the current therapeutic approach is purely symptomatic relying on a combination of nonpharmacological and off-label pharmacological approaches lacking quality evidence of effectiveness.

Pharmacological treatment has been primarily focused on common neuropsychiatric symptoms in FTD, with less emphasis on executive dysfunction and working memory deficits. Selective serotonin reuptake inhibitors (SSRIs) are often used to treat FTD patients due to the established association between FTD and presynaptic serotonin deficit, alongside a loss of cortical serotonergic innervation [2]. This pathophysiological basis for SSRI use is further supported by the favourable response to SSRIs of similar behavioural symptoms in patients with psychiatric disorders. Positive effects in FTD have been demonstrated in some small open-label trials or case series [3–9]. SSRIs with lower anticholinergic side effects, such as citalopram and escitalopram, are typically preferred [10].

Antipsychotics are also often used off-label in FTD. However, their use needs close surveillance because of considerable risk of extrapyramidal side effects and the black box warning when treating dementia-related behavioural symptoms in the elderly. Apart from the serotonin deficit, FTD is also associated with a dopaminergic deficit [11] and there is evidence that the mesolimbic and mesocortical dopaminergic pathway changes are related to the behavioural symptoms [12]. But still, several antipsychotics have demonstrated improvement in behavioural symptoms in FTD, including delusions or agitation, and in caregiver burden [13–17]. Because of the effect of antipsychotics on the nigrostriatal pathway, antipsychotics with lower D2-receptor blocking affinity, such as quetiapine, are commonly preferred. A case series describing medication responses in FTD showed that quetiapine improved agitation in three patients [17].

Trazodone, a mixed agonist and antagonist of various serotonin receptors and antagonist of adrenergic receptors, is a third option often prescribed for neuropsychiatric symptoms in FTD. Trazodone

increases extracellular serotonin in the frontal lobes and has been proved to decrease agitation and aggression and to improve sleep in FTD [18]. A randomized controlled trial with trazodone in FTD in a cohort of 26 cases showed a significant improvement in the Neuropsychiatric Inventory (NPI) total score, mainly based on improvements in irritability, agitation, depressive symptoms and eating disorders [19].

Other medications occasionally considered in behavioural manifestations of FTD include anticonvulsants, stimulants, benzodiazepines and other antidepressants. Acetylcholinesterase inhibitors, especially donepezil, frequently used to improve cognitive functioning in Alzheimer's disease, were proved to worsen the neuropsychiatric symptoms without cognitive improvement in patients with FTD in multiple studies [2, 18, 20–23]. Memantine is also not an effective treatment for FTD [24–28].

Altogether, trial-based evidence for symptomatic pharmacological treatment of behavioural disturbances in FTD is scarce despite their significant burden on both patients and caregivers. This expert opinion review aims to provide guidance for pharmacological treatment of behavioural symptoms that severely impact the patient's and family's wellbeing.

The symptoms queried were selected based on clinical expertise of the FTD disease group. They were deliberately meant to be concrete and directly taken from clinical experience rather than querying more general classes of symptom clusters.

METHOD

This study is an expert opinion review based on the current practices within the 29 specialized centres of the FTD disease group of the European Reference Network for Rare Neurological Diseases (ERN-RND). ERN-RND was established in 2017 as one of the 24 European Reference Networks by the European Board of Member States and has currently 71 members from 24 EU countries. ERN-RND aims to improve the healthcare of rare disease patients in the EU and to reduce inequalities in how healthcare is being provided for rare disease patients.

Neurologists or psychiatrists, who are faculty members at each participating ERN-RND site and are clinically involved in the FTD clinical programme, were invited to participate in a survey. The primary objective was to evaluate current clinical practices concerning drug management for behavioural manifestations of FTD at their respective

sites. The study encompassed 14 common behavioural problems and, for each of them, respondents were presented with a list of 20 drug options. This list also included 'none' and 'other' to allow physicians to specify if the preferred drug was not on the provided list.

The selected 14 behavioural problems in this survey consisted of physical aggression, verbal aggression, obsessive delusions, impulsivity, nightly unrest, self-harm due to obsessive motor behaviour, sexual disinhibition, motor unrest, intentional self-injury, apathy, hyperphagia, perseverative somatic complaints, rigidity of thought and loss of empathy. The choice of these behavioural disturbances, grounded in common clinical complaints, was determined by consensus by the leading study physicians (RV, HS, DS, RR). Obsessive delusions are persistent repetitive delusions that focus on specific content over an extended period (months). Self-harm due to obsessive motor behaviour refers to harmful consequences to the patient's physical integrity caused by obsessive motor behaviour, such as repetitive tapping or rubbing or obsessive cleaning leading to abrasures and superficial wounds. Intentional self-injury refers to motor behaviours deliberately aimed at causing harm to the body, such as cutting out pigmented spots or cutting body parts with scissors. Perseverative somatic complaints are perseverative physical complaints for which no organic cause can be identified. Apathy denotes a lack of motivation reflected in decreased goal-directed behaviours, cognitions and emotions. Nightly unrest is characterized by increased nocturnal activity and difficulty remaining in bed. Motor unrest describes restlessness and stereotypical movements. Prior to the survey, the participants were informed about the list of symptoms, and the above definitions, including the examples, were given for terms that may not have been clear from the start.

Most of the specific symptoms queried can be mapped onto one or more general classes from the different FTD symptom classification schemes (Table 1). According to the Rascovsky et al. (2011) consensus criteria [29], physical and verbal aggression, impulsivity and sexual disinhibition would probably be classified under behavioural disinhibition. Obsessive delusions, self-harm due to obsessive motor behaviour, intentional self-injury, perseverative somatic complaints and rigidity of thought would probably be classified under perseverative, stereotyped or compulsive/ritualistic behaviour. Apathy corresponds to apathy or inertia in the Rascovsky et al. (2011) classification, loss of empathy corresponds to loss of sympathy or empathy, and hyperphagia is mentioned under hyperorality and dietary changes in the Rascovsky et al. criteria. Nightly and motor unrest are more difficult to classify under one of the mentioned categories and can result from disinhibition, apathy with low daytime activity or from obsessive-repetitive behaviours.

The 18 drug options included trazodone, sodium valproate, sertraline, semaglutide, risperidone, quetiapine, promazine, periciazine, oxazepam, olanzapine, mirtazapine, methylphenidate, hydroxyzine, fluoxetine, carbamazepine, bupropion, amitriptyline and (es)citalopram, plus 'none' and 'other'. The choice of drugs was grounded on clinical practices, previous studies and theoretical mechanisms of action, as described above, and was also determined by consensus by the leading study physicians.

Participating physicians were instructed to respond according to their actual clinical practice. They were first asked about the availability of each mentioned drug in their respective countries. Subsequently, for each of the 14 behavioural disturbances:

TABLE 1 Categories of different FTD symptom classification schemes wherein the queried behavioural symptoms would fall.

Behavioural symptom	Rascovsky et al. [29]	NPI-Q	GenFi neuropsychiatric clinical questionnaire [30]
Physical aggression	Behavioural disinhibition	Agitation/aggression	Agitation/aggression
Verbal aggression	Behavioural disinhibition	Agitation/aggression	Agitation/aggression
Obsessive delusions	Obsessive-repetitive behaviour	Delusions	Delusions/hallucinations
Impulsivity	Behavioural disinhibition	Disinhibition	Irritability/lability
Nightly unrest		Night-time behavioural disturbances	Impaired sleep
Self-harm due to obsessive motor behaviour	Obsessive-repetitive behaviour	Aberrant motor behaviour	Aberrant motor behaviour
Sexual disinhibition	Behavioural disinhibition	Disinhibition	Hypersexuality
Motor unrest		Agitation/aggression	Aberrant motor behaviour
Intentional self-injury	Obsessive-repetitive behaviour		Aberrant motor behaviour
Apathy	Apathy	Apathy/indifference	
Hyperphagia	Hyperorality and dietary changes	Appetite/eating disturbance	
Perseverative somatic complaints	Obsessive-repetitive behaviour	Anxiety, dysphoria	
Rigidity of thought	Obsessive-repetitive behaviour		
Loss of empathy	Loss of sympathy and empathy	Apathy/indifference	

Note: The Rascovsky criteria form the basis for the behavioural module of the CDR plus NACC FTLD rating.

Abbreviations: CDR plus NACC FTLD, Clinical Dementia Rating plus National Alzheimer's Coordinating Centre Frontotemporal Lobar Degeneration; GenFi, Genetic Frontotemporal Dementia Initiative; NPI-Q, Neuropsychiatric Inventory Questionnaire.

1. Participants were asked to indicate by ticking a box if none of the suggested drug options was recommended. Alternatively, they were prompted to rank their top three recommended drug treatments with the instruction, 'Please choose from the list of the following drug therapies the three most highly recommended'. An option 'other' was provided to allow physicians to specify any additional drugs they might recommend beyond the given list.
2. Similarly, they were asked to tick a box if none of the drug options was advised against. Alternatively, physicians could rank the three drug treatment options they considered strongly contraindicated with the instruction, 'Please choose from the list of the following drug therapies the three certainly not to be used'.

It is worth noting that participating physicians were also questioned about nonpharmacological treatments. However, in order to maintain conciseness, the decision was made to exclude this information from the final version of this article.

Statistical analysis

Two key indicators were computed to summarize the most recommended and the most contraindicated treatments for each behavioural disturbance: (1) the percentage of respondents amongst the participating physicians who selected a treatment regardless of its rank and (2) a weighted score (WS) that considered the rank. The WS was calculated by considering the average rank or mean score based on the physicians' ranking. Specifically, the first choice was assigned 3 points, the second choice 2 points, the third choice 1 point, and subsequent choices, if any, received 0.5 points, with no points awarded if not chosen. To estimate 95% credibility intervals for both indicators concerning each behavioural disturbance and treatment, 1000 bootstrapped samples were run for each statistical analysis.

To identify symptoms for which physicians recommended or advised against similar treatments, two principal component analyses (PCA) were performed, one focusing on recommended treatments and the other on contraindicated treatments. Each PCA was based on the percentage of physicians who selected a treatment, regardless of its rank. The dataset used for the analyses consisted of treatments as observations and behavioural disturbances as variables. This dataset structure allowed the exploration of patterns in treatment recommendations and contraindications across various behavioural symptoms.

RESULTS

Recommended treatments

Twenty-one respondents from 19 centres across 13 countries participated. Depending on the symptoms, physicians exhibited varying degrees of willingness to prioritize treatments, as displayed in

Figures 1a and S1. Notably, participating physicians were most comfortable with ranking recommended treatments in the case of physical aggression (100% ordered at least three treatments, as requested in the instructions), verbal aggression (90.5% ordered at least three treatments, and 9.5% recommended two treatments), obsessive delusions (100% at least three) and impulsivity (100% also ordering at least three).

In contrast, when addressing loss of empathy, 66.7% of the physicians (14 out of 21) opted not to recommend any proposed drug. Similarly, for rigidity of thought, 42.9% of physicians refrained from proposing or choosing any of the suggested treatments.

In several behavioural disturbances such as physical aggression, verbal aggression, perseverative somatic complaints or rigidity of thought, a clear consensus emerged with physicians favouring one, two or three treatments. However, for other conditions such as sexual disinhibition, self-injury or hyperphagia, no such consensus was reached.

Amongst the behavioural disturbances, antipsychotics emerged as the most recommended for half of the symptoms (7/14), whilst SSRIs were the primary choice for 36% (5/14) of the symptoms (Figures 2a and 3a). Within the antipsychotic category, quetiapine was numerically the most selected treatment for six behavioural symptoms, including physical aggression (76.2% of all participating physicians, with a WS of 1.7 for both quetiapine and risperidone), obsessive delusions and verbal aggression (71.4% each; WS=1.5 and WS=1.6 respectively), nightly unrest and self-harm due to obsessive motor behaviour (61.9% each, WS=1.3) and sexual disinhibition (52.4%, WS=0.9). Risperidone was the preferred choice for self-injury (52.4%, WS=1.2).

Within the SSRIs, sertraline was the most selected treatment for four behavioural symptoms: perseverative somatic complaints (57.1%, WS=1.3), rigidity of thought (47.6%, WS=1.0), hyperphagia (38.1%, WS=0.9) and loss of empathy (23.8%, WS=0.5). (Es) citalopram was the most selected for impulsivity (66.7%, WS=1.5). For motor unrest, trazodone was the preferred treatment (42.9%, WS=1.0), whilst bupropion was favoured for apathy (52.4%, WS=1.1).

Concluding, at least two-thirds of physicians selected at least one identical treatment for the four following behavioural symptoms: physical aggression, verbal aggression, obsessive delusions and impulsivity. These were also the four symptoms with a mean rank (i.e., WS) higher than 1.5, namely for two antipsychotics, emphasizing the consistency in physician preferences for these specific symptoms.

Figure 4 shows the PCA. The first component of the PCA captures 67.4% of the dataset variance, whilst the second dimension accounts for 18.4%. The first dimension primarily represents a size effect, with all symptom coefficients being positive: treatments located further to the right on the figure exhibit higher citation counts. Conversely, the second dimension distinguishes between treatments with similar citation patterns based on difference in target symptoms.

Based on the PCA, sertraline and (es)citalopram are close and thus similarly recommended for hyperphagia, perseverative somatic




FIGURE 1 Distribution of physicians by the number of treatments selected for each behavioural symptom recommended by physicians (a) or marked as contraindicated (b). The symptoms are ordered along the x-axis, with those having the highest number of physicians not selecting any recommended treatment on the right, whilst symptoms where all physicians chose at least one treatment are positioned on the left. The same ordering was applied in the contraindication figure. For example, in the case of loss of empathy: amongst the 21 physicians 14 (67%) did not recommended any treatment, one (5%) recommended a single treatment and six (29%) recommended three treatments.

complaints and rigidity of thought, whereas they are rarely suggested for physical aggression and nightly unrest. These two treatments are also endorsed for apathy and loss of empathy, alongside bupropion and fluoxetine. Quetiapine and risperidone are frequently co-cited, particularly for nightly unrest and physical aggression (with olanzapine for physical aggression), but are seldom mentioned for hyperphagia, perseverative somatic complaints and rigidity of thought. For other symptoms, although quetiapine and risperidone are the most frequently cited, sertraline and (es)citalopram are also commonly recommended.

However, clustering is not able to encompass the remaining behavioural symptoms, i.e. impulsivity, motor unrest, sexual disinhibition, apathy and obsessive delusions. For these five symptoms either different drug classes or both SSRIs and antipsychotics are advised.

Contraindicated treatments

The task of selecting contraindicated treatments proved more challenging for physicians compared to making recommendations (Figure 1b). For all behavioural symptoms there are at least four (19%) physicians who did not select any treatment, emphasizing the complexity and hesitancy in identifying contraindicated options.

There was also a varying response rate across symptoms. Physical aggression and verbal aggression had the highest response rates (81% of physicians selected at least one treatment), whilst loss of empathy had the lowest response rate (43%).

Furthermore, the results varied when considering the percentage of physicians who selected a treatment regardless of its rank (Figure 2b) and the WS that considered the rank (Figure 3b).

Considering the percentage regardless of rank, bupropion was selected as most contraindicated in nine behavioural symptoms: physical aggression (selected by 42.8% of physicians), obsessive delusions (38.1%), impulsivity, self-harm, sexual disinhibition and motor unrest (33.4% each), nightly unrest, self-injury and rigidity of thought (23.8% each). Amitriptyline was identified as the most contraindicated for verbal aggression (42.8%), olanzapine for hyperphagia (38.1%), oxazepam for perseverative somatic complaints (23.8%), promazine for loss of empathy (23.8%) and trazodone for apathy (28.6%).

Considering the WS for contraindicated treatments, amitriptyline was the most contraindicated in three symptoms including verbal aggression (WS=1), physical aggression (WS=0.9) and apathy (WS=0.5). Bupropion was the most selected as contraindicated in seven behavioural symptoms: obsessive delusions and motor unrest (WS=0.9 each), impulsivity and self-harm (WS=0.8 each), sexual disinhibition (WS=0.7), self-injury (WS=0.6) and




FIGURE 2 The top five most selected treatments by physicians for each behavioural symptom recommended by physicians (a) or marked as contraindicated (b). This figure shows, for each behavioural symptom and drug, the percentages of physicians (out of 21) who selected the drug, regardless of the rank, with their 95% bootstrapped confidence intervals. The n value in parentheses for each symptom represents the number of physicians who selected at least one treatment, giving insight into the sample size contributing to the calculations.

nightly unrest ($WS=0.5$). Oxazepam was the most contraindicated for rigidity of thought ($WS=0.6$), perseverative somatic complaints ($WS=0.6$) and loss of empathy ($WS=0.4$). Olanzapine was the most contraindicated for hyperphagia ($WS=0.8$). These results showed that there is no clear consensus between the 21 physicians concerning the contraindicated treatments, which is probably influenced by individual clinical experiences, patient profiles and varying interpretations of contraindications for specific behavioural symptoms.

DISCUSSION

Our study looked at the pharmacological preferences of neurologists and psychiatrists, all members of the ERN-RND network, with expertise in cognitive disorders for common behavioural symptoms in FTD. The main findings are as follows: (i) there was a strong consensus for drug therapy in four specific behavioural manifestations (verbal aggression, physical aggression, obsessive delusions and impulsivity); (ii) therapeutic options for other




FIGURE 3 The top five treatments with highest mean score for each behavioural symptom recommended by physicians (a) or marked as contraindicated (b). This figure portrays the mean score allocated to a treatment per behavioural symptom. The scoring system is structured as follows: the first choice is awarded 3 points, the second choice receives 2 points, the third choice is given 1 point, subsequent choices, if any, get 0.5 points each, and, if the physician did not choose any treatment, 0 points are assigned. The *n* value in parentheses for each symptom represents the number of physicians who selected at least one treatment, providing context about the sample size contributing to the mean scores.

behavioural symptoms were more heterogeneous; and (iii) either SSRIs or antipsychotics are most often advised depending on the target symptom.

Our results indicated a strong consensus amongst participating physicians that drug therapy was warranted for four specific behavioural disturbances: verbal aggression, physical aggression, impulsivity and obsessive delusions. It can be hypothesized that the reason for this common viewpoint across all ERN-RND centres is

that these symptoms both represent an important burden for the patient and/or caregiver and tend to respond favourably to pharmacological treatment.

The PCA in this study indicates distinctive patterns in pharmacological preferences for behavioural symptoms in FTD based on therapeutic preferences for SSRI versus antipsychotics. This classification was an interesting *post hoc* finding as a result of statistical data analysis and seems to reflect not only therapeutic habitudes




FIGURE 4 Results of the PCA based on the percentage of physicians who selected a treatment, regardless of its rank, using the treatments as observations and the behavioural disturbances as variables. PCA, principal components analysis.

but probably also underlying expert experience. One group, encompassing perseverative somatic complaints, rigidity of thought, hyperphagia and loss of empathy, are preferentially treated with SSRIs. These manifestations may result from emotional disturbances, interrupted orbitofrontal and dorsolateral prefrontal circuits and serotonergic deficits [11, 31, 32]. Conversely, antipsychotics are preferred for another group of symptoms, including physical aggression, verbal aggression, self-injury, self-harm due to obsessive motor behaviour, and nightly unrest. These manifestations may reflect loss of self-control, aberrant motor behaviour and auto/hetero-aggressivity and relate to cortico-subcortical circuits, mediofrontal areas and noradrenaline and dopamine alterations [31, 32].

The common use of SSRIs aligns the known presynaptic serotonin deficits and loss of cortical serotonergic innervation in FTD [2]. The preference for quetiapine may stem from its classification as a second-generation neuroleptic with low affinity to the D2 receptor.

Principal component analysis is a standard statistical way to detect the latent structure in the data. The data are composed of the response options provided by the experts who participated. The fact that symptoms can be grouped based on similar drug treatment decisions does not contradict the importance of individually tailored management of symptoms. It indicates that the individually tailored management happens in a relatively consistent way across different centres.

Furthermore, trazodone was a top five choice in 10 out of 14 behavioural symptoms and the first choice for motor unrest, mirtazapine was the second choice for nightly unrest and methylphenidate and bupropion were ranked highly for apathy. Semaglutide was advised for hyperphagia by one in four physicians. Drugs that never made it into the top five advised medications were sodium valproate, pericazine, hydroxyzine, carbamazepine and amitriptyline.

Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.

Study strengths

In this study, there was a large participation rate consisting of 21 physicians from the FTD group of the ERN-RND, specialized in the regular treatment of patients with FTD. This expert review represents a pioneering effort in the field, providing insights into recommended treatments for individuals with FTD. As the first of its kind, this study holds significant importance in advancing our understanding of FTD management from real-life data. The findings from this research have the potential to serve as a valuable resource, guiding the selection of future drugs and informing the design of forthcoming clinical trials aimed at enhancing FTD treatment strategies.

Study limitations

The description of current practices in expert centres should be viewed with caution, as it does not serve as proof of efficacy. Whilst these practices provide valuable insights into the real-world application of treatments, they do not necessarily establish their effectiveness. It is important to recognize that relying solely on clinical experience for defining target symptoms might vary, as different experts may prioritize symptoms differently. Certain specific symptoms, such as loss of manners, and bothersome symptoms like depression and anxiety were not queried in this study. Furthermore, the behavioural symptoms queried were concrete and directly taken from clinical experience rather than more general classes of

symptom clusters. Without using a standardized set of symptoms, there is a risk of subjectivity in identifying and addressing target symptoms, highlighting the need for more rigorous and objective criteria in the evaluation and development of treatment approaches. Finally, nonpharmacological measures were also evaluated in the study; however, to maintain conciseness, these specific data were excluded from the final version.

CONCLUSIONS

This study reveals several insights regarding the treatment preferences for behavioural symptoms associated with FTD. The highest consensus for treatment was observed for physical and verbal aggression, impulsivity and obsessive delusions. This suggests a more unified approach amongst physicians in addressing these specific behavioural challenges associated with FTD. PCA suggests a distinction between a group which are best treated with SSRIs and a group for which antipsychotics are considered more effective.

Furthermore, trazodone was a top five choice in 10 out of 14 behavioural symptoms, mirtazapine was the second choice for nightly unrest and methylphenidate and bupropion were ranked highly for apathy. Semaglutide was advised for hyperphagia by one in four physicians. Drugs that never made it into the top five advised medications were sodium valproate, periciazine, hydroxyzine, carbamazepine and amitriptyline. Bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.

The survey data offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD. Additionally, the survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms impacting the wellbeing of both patients and their families. This expertise can aid in developing more tailored and effective therapeutic approaches for managing FTD-associated behaviours.

AUTHOR CONTRIBUTIONS

Casper Wittebrood: Writing – original draft; writing – review and editing; formal analysis; methodology; visualization; conceptualization; data curation. **Marina Boban:** Writing – review and editing; investigation. **Annchiara Cagnin:** Investigation; writing – review and editing. **Sabina Capellari:** Investigation; writing – review and editing. **François-Laurent De Winter:** Investigation; writing – review and editing. **Atbin Djamshidian:** Investigation; writing – review and editing. **Manuel Menéndez González:** Investigation; writing – review and editing. **Lena E. Hjermand:** Investigation; writing – review and editing. **Lenka Krajcovicova:** Investigation; writing – review and editing. **Johanna Krüger:** Investigation; writing – review and editing. **Johannes Levin:** Investigation; writing – review and editing. **Kathrin Reetz:** Investigation; writing – review and editing. **Eloy Rodriguez Rodriguez:** Investigation; writing – review and editing. **JD Rohrer:** Investigation; writing – review and editing. **Tim Van Langenhove:** Investigation;

writing – review and editing. **Carola Reinhard:** Investigation; writing – review and editing. **Holm Graessner:** Investigation; writing – review and editing. **Robert Rusina:** Investigation; writing – review and editing. **Dario Saracino:** Investigation; writing – review and editing; data curation; supervision; methodology. **Marion Houot:** Visualization; formal analysis. **Harro Seelar:** Investigation; writing – review and editing. **Rik Vandenberghe:** Funding acquisition; investigation; conceptualization; validation; writing – review and editing; supervision.

AFFILIATIONS

¹Department of Neurology, University Hospital Leuven, Leuven, Belgium

²Department of Cognitive Neurology, Referral Centre for Cognitive Neurology and Neurophysiology, University Hospital Centre Zagreb, Zagreb, Croatia

³School of Medicine, University of Zagreb, Zagreb, Croatia

⁴Department of Neuroscience and Padua Neuroscience Centre, University of Padua, Padua, Italy

⁵Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy

⁶IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

⁷Department of Neurology, Medical University Innsbruck, Innsbruck, Tyrol, Austria

⁸Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain

⁹Department of Medicine, Universidad de Oviedo, Oviedo, Spain

¹⁰Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain

¹¹Department of Neurology, Neurogenetics Clinic and Clinical Trial Unit, Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

¹²First Department of Neurology, St Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic

¹³Department of Neurology, Neurocentre, Oulu University Hospital, Oulu, Finland

¹⁴Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland

¹⁵MRC, Oulu University Hospital, Oulu, Finland

¹⁶Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany

¹⁷German Centre for Neurodegenerative Diseases, Munich, Germany

¹⁸Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

¹⁹Department of Neurology, RWTH Aachen University, Aachen, Germany

²⁰Neurology Service, Marqués de Valdecilla University Hospital, Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain

²¹CIBERNED, Network Centre for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain

²²Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

²³Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK

²⁴Department of Neurology, Cognitive Centre, Ghent University Hospital, Ghent, Belgium

²⁵Centre for Rare Diseases and Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany

²⁶Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

²⁷Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany

²⁸Department of Neurology, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic

²⁹Paris Brain Institute, Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, AP-HP-Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France

³⁰Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP-Hôpital Pitié-Salpêtrière, Paris, France

³¹Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière Hospital, Paris, France

³²Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France

³³Clinical Investigation Centre for Neurosciences, Institut du Cerveau (ICM), Pitié-Salpêtrière Hospital, Paris, France

³⁴Department of Neurology and Alzheimer Centre Erasmus MC, Erasmus MC University Medical Centre, Rotterdam, The Netherlands

ACKNOWLEDGEMENTS

This study has been supported by ERN-RND, which is partly co-funded by the European Union within the framework of the ERN-RND ERN-2022—Framework Partnership Agreement 2022–23.

CONFLICT OF INTEREST STATEMENT

Johannes Levin reports receiving speaker fees from Bayer Vital, Biogen, Eisai, TEVA, Zambon, Merck, and Roche, as well as consulting fees from Axon Neuroscience, Eisai, and Biogen. He has also received author fees from Thieme Medical Publishers and W. Kohlhammer GmbH Medical Publishers. Johannes Levin is the inventor of a patent titled "Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies" (EP 23 156 122.6) filed by LMU Munich. Additionally, he serves as the Chief Medical Officer for MODAG GmbH, is a beneficiary of MODAG GmbH's phantom share program, and is the inventor of a patent titled "Pharmaceutical Composition and Methods of Use" (EP 22 159 408.8) filed by MODAG GmbH. All of these activities are unrelated to the work submitted. Jonathan Rohrer has provided consultancy services or served on advisory boards for Novartis, Wave Life Sciences, Preval, Alector, Aviado Bio, Takeda, Arkuda Therapeutics, and Denali Therapeutics.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Casper Wittebrood  <https://orcid.org/0009-0004-2600-4736>

Anchiara Cagnin  <https://orcid.org/0000-0002-0635-4884>

Sabina Capellari  <https://orcid.org/0000-0003-1631-1439>

Kathrin Reetz  <https://orcid.org/0000-0002-9730-9228>

REFERENCES

- Magrath Guimet N, Zapata-Restrepo LM, Miller BL. Advances in treatment of frontotemporal dementia. *J Neuropsychiatry Clin Neurosci.* 2022;34(4):316–327. doi:[10.1176/appi.neuropsych.21060166](https://doi.org/10.1176/appi.neuropsych.21060166)
- Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. *Neurology.* 2006;66(1):17–22. doi:[10.1212/01.wnl.0000191304.55196.4d](https://doi.org/10.1212/01.wnl.0000191304.55196.4d)
- Prodan CI, Monnot M, Ross ED. Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. *J Neurol Neurosurg Psychiatry.* 2009;80(12):1416–1417. doi:[10.1136/jnnp.2009.173260](https://doi.org/10.1136/jnnp.2009.173260)
- Anneser JMH, Jox RJ, Borasio GD. Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. *Amyotroph Lateral Scler.* 2007;8(3):189–190. doi:[10.1080/17482960601073543](https://doi.org/10.1080/17482960601073543)
- Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. *Mov Disord.* 2005;20(6):742–745. doi:[10.1002/mds.20465](https://doi.org/10.1002/mds.20465)
- Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. *Dement Geriatr Cogn Disord.* 2004;17(3):117–121. doi:[10.1159/000076343](https://doi.org/10.1159/000076343)
- Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanctôt KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. *Am J Geriatr Psychiatry.* 2012;20(9):789–797. doi:[10.1097/JGP.0b013e31823033f3](https://doi.org/10.1097/JGP.0b013e31823033f3)
- Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. *J Clin Psychiatry.* 1997;58(5):212–216.
- Manoochehri M, Huey ED. Diagnosis and management of behavioral issues in frontotemporal dementia. *Curr Neurol Neurosci Rep.* 2012;12(5):528–536. doi:[10.1007/s11910-012-0302-7](https://doi.org/10.1007/s11910-012-0302-7)
- Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline. *Int Clin Psychopharmacol.* 2014;29(4):185–196. doi:[10.1097/YIC.0000000000000023](https://doi.org/10.1097/YIC.0000000000000023)
- Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. *Brain.* 2018;141(5):1263–1285. doi:[10.1093/brain/awx327](https://doi.org/10.1093/brain/awx327)
- Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. *Neurology.* 2002;58(10):1489–1493. doi:[10.1212/WNL.58.10.1489](https://doi.org/10.1212/WNL.58.10.1489)
- Reeves RR, Perry CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. *J Clin Psychopharmacol.* 2013;33(1):145–146. doi:[10.1097/01.jcp.0000426190.64916.3b](https://doi.org/10.1097/01.jcp.0000426190.64916.3b)
- Fellgiebel A, Müller MJ, Hiemke C, Bartenstein P, Schreckenberger M. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. *World J Biol Psychiatry.* 2007;8(2):123–126. doi:[10.1080/15622970601016538](https://doi.org/10.1080/15622970601016538)
- Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. *Am J Alzheimers Dis Other Dement.* 2003;18(4):205–214. doi:[10.1177/153331750301800410](https://doi.org/10.1177/153331750301800410)
- Curtis RC, Resch DS. Case of Pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. *J Clin Psychopharmacol.* 2000;20(3):384–385. doi:[10.1097/00004714-200006000-00018](https://doi.org/10.1097/00004714-200006000-00018)
- Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. *Am J Alzheimers Dis Other Dement.* 2002;17(5):267–272. doi:[10.1177/153331750201700504](https://doi.org/10.1177/153331750201700504)
- Pressman PS, Miller BL. Diagnosis and management of behavioral variant frontotemporal dementia. *Biol Psychiatry.* 2014;75(7):574–581. doi:[10.1016/j.biopsych.2013.11.006](https://doi.org/10.1016/j.biopsych.2013.11.006)
- Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dement Geriatr Cogn Disord.* 2004;17(4):355–359. doi:[10.1159/000077171](https://doi.org/10.1159/000077171)
- Mendez MF, Shapira JS, McMurtry A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. *Am J Geriatr Psychiatry.* 2007;15(1):84–87. doi:[10.1097/01.JGP.00000231744.69631.33](https://doi.org/10.1097/01.JGP.00000231744.69631.33)
- Young JJ, Lavakumar M, Tampi D, Balachandran S, Tampi RR. Frontotemporal dementia: latest evidence and clinical implications. *Ther Adv Psychopharmacol.* 2018;8(1):33–48. doi:[10.1177/2045125317739818](https://doi.org/10.1177/2045125317739818)
- Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. *Alzheimer Dis Assoc Disord.* 2007;21(4):S79–S87. doi:[10.1097/WAD.0b013e31815c345e](https://doi.org/10.1097/WAD.0b013e31815c345e)

23. Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. *Geriatr Gerontol Int*. 2013;13(2):506-507. doi:[10.1111/j.1447-0594.2012.00956.x](https://doi.org/10.1111/j.1447-0594.2012.00956.x)
24. Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2013;12(2):149-156. doi:[10.1016/S1474-4422\(12\)70320-4](https://doi.org/10.1016/S1474-4422(12)70320-4)
25. Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. *J Alzheimers Dis*. 2011;23(4):749-759. doi:[10.3233/JAD-2010-101632](https://doi.org/10.3233/JAD-2010-101632)
26. Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. *Alzheimer Dis Assoc Disord*. 2009;23(3):211-217. doi:[10.1097/WAD.0b013e318197852f](https://doi.org/10.1097/WAD.0b013e318197852f)
27. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia. *Alzheimer Dis Assoc Disord*. 2007;21(2):164-166. doi:[10.1097/WAD.0b013e318047df5d](https://doi.org/10.1097/WAD.0b013e318047df5d)
28. Diehl-Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. *Int J Geriatr Psychiatry*. 2008;23(7):754-759. doi:[10.1002/gps.1973](https://doi.org/10.1002/gps.1973)
29. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134(9):2456-2477. doi:[10.1093/brain/awr179](https://doi.org/10.1093/brain/awr179)
30. Samra K, Macdougall A, Peakman G, et al. Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales. *J Neurol Neurosurg Psychiatry*. 2023;94(5):357-368. doi:[10.1136/jnnp-2022-330152](https://doi.org/10.1136/jnnp-2022-330152)
31. Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. *Neurochem Int*. 2008;52(6):1052-1060. doi:[10.1016/j.neuint.2007.10.018](https://doi.org/10.1016/j.neuint.2007.10.018)
32. Whiteside DJ, Holland N, Tsvetanov KA, et al. Synaptic density affects clinical severity via network dysfunction in syndromes associated with frontotemporal lobar degeneration. *Nat Commun*. 2023;14(1):8458. doi:[10.1038/s41467-023-44307-7](https://doi.org/10.1038/s41467-023-44307-7)

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Wittebrood C, Boban M, Cagnin A, et al. Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND). *Eur J Neurol*. 2024;31:e16446. doi:[10.1111/ene.16446](https://doi.org/10.1111/ene.16446)



European
Reference
Networks

https://ec.europa.eu/health/ern_en



European
Reference
Network

for rare or low prevalence
complex diseases

 **Network**

Neurological Diseases
(ERN-RND)

 **Coordinator**

Universitätsklinikum
Tübingen — Deutschland

www.ern-rnd.eu

Co-funded by the European Union

